Neuropathology and amyloid-beta spectrum in a Bapineuzumab immunotherapy recipient

Manuscript Number: 

10-1809R1

Author(s): 
Thomas G. Beach, Ian D. Daugs, Jesse M. Hunter, Tyler A. Kokjohn, Chera L. Maarouf, Alex E. Roher, Marwan N. Sabbagh

Disclosures

Thomas G. Beach

  • Grants
    • Agency: 
      Avid Radiopharmaceuticals
      Dates: 
      2009-present
    • Agency: 
      Bayer Healthcare
      Dates: 
      2010-present
    • Agency: 
      GE Healthcare
      Dates: 
      2010-present

Ian D. Daugs

  • Nothing to Disclose

Jesse M. Hunter

  • Nothing to Disclose

Tyler A. Kokjohn

  • Nothing to Disclose

Chera L. Maarouf

  • Nothing to Disclose

Alex E. Roher

  • Nothing to Disclose

Marwan N. Sabbagh

  • Consulting Fees:
    MNS receives grant support (clinical trials) from BMS, Avid, GE, Bayer, Baxter, Wyeth, Janssen, Lilly and Medivation. MNS is also on the Consultant/advisory board for Janssen/Pfizer, Amerisciences, Eisai, Takeda and GSK, and
    Patents/Royalties
    receives royalties from Amerisciences and Wiley.
    Grants
    • Agency: 
      BMS
      Dates: 
      2007-
    • Agency: 
      Avid
      Dates: 
      2008-
    • Agency: 
      GE
      Dates: 
      2010-
    • Agency: 
      Baxter
      Dates: 
      2007-
    • Agency: 
      Bayer
      Dates: 
      2009-
    • Agency: 
      Wyeth
      Dates: 
      2005-
    • Agency: 
      Lilly
      Dates: 
      2008-
    • Agency: 
      Janssen
      Dates: 
      2008-
    • Agency: 
      Medivation
      Dates: 
      2004